| Date | Title | Description |
| 08.01.2026 | Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria | Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian li... |
| 07.01.2026 | Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease | Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease
Collaboration secures clinical supply needed ... |
| 19.12.2025 | New Publication in Nature Communications Demonstrates the Therapeutic Utility of Targeting Synthetic Neoantigens Generated by KRAS G12C Inhibitors | Findings shared in article co-authored by Aethon Therapeutics scientists and NYU researchers support the hypothesis that combining covalent inhibitors and T cell engagers can overcome drug resistance in KRAS-mutated cancers
New York, New Yo... |
| 16.12.2025 | Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer | Senior biopharma executive with nearly 20 years of strategy, operational and business development experience will help lead Replicate's corporate strategy, partnerships and next chapter of growth
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Rep... |
| 12.12.2025 | Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium | Safety profile of Invikafusp alfa + TRODELVY® is consistent with the known profiles of each agent
Invikafusp alfa demonstrates selective expansion of Vβ6/10 T cells when combined with TRODELVY® in previously treated metastatic breast cancer... |
| 10.12.2025 | Apple Tree Partners Initiates Voluntary U.S. Chapter 11 Cases in Delaware to Restructure Operations | NEW YORK, December 10, 2025 (PR Newswire) – Apple Tree Partners (“ATP”), a leading life sciences venture capital firm, has announced that on December 9, 2025, certain ATP affiliates filed voluntary petitions for Chapter 11 relief in the Uni... |
| 04.12.2025 | Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate’s Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America | Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate’s novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis
Replicate to provide GMP material for clinical trials and transfer ... |
| 07.11.2025 | New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer | Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety profile easily managed in outpatient setting; ... |
| 07.11.2025 | Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025 | 20% ORR and 80% DCR observed as monotherapy in TMB-H tumors across seven major solid tumor types, including colorectal, lung, breast, gastric, gastroesophageal junction (GEJ), head and neck, and bladder cancers
Clinical activity was consist... |
| 17.10.2025 | Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at... | 20.5% ORR and 79% DCR observed in heavily pretreated TMB-H or MSI-H/dMMR tumors across six major solid tumor types, including colorectal, lung, breast, gastric, GEJ, and head and neck cancers
52% of patients experienced target-lesion tumor ... |
| 15.10.2025 | Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 | Lead program from TriSTAR T cell engager platform targets Nectin-4, a clinically validated tumor antigen overexpressed across multiple solid tumors, including urothelial cancer, NSCLC, TNBC, and esophageal cancer
Collaboration with the Nati... |
| 09.10.2025 | Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion | Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share
Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therap... |
| 03.10.2025 | Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif., October 3, 2025 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, today announced the presentation of updated Phase ... |
| 24.09.2025 | Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000 | Eight month follow-up data published in Communications Medicine, a Nature portfolio journal
Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for rabies, an ongoing global public health con... |
| 24.09.2025 | Marengo to Present Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoin... | Data to be presented from the STARt-001 trial demonstrating invikafusp’s single-agent anti-tumor activity in diverse, large cancer indications
CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage bio... |
| 22.09.2025 | Nereid Therapeutics Scientific Co-Founder Clifford Brangwynne Named a 2025 Keio Medical Science Prize Laureate | September 22, 2025/ − Clifford Brangwynne, Ph.D., co-founder of Nereid Therapeutics and professor of chemical and biological engineering at Princeton University, has been selected as a 2025 recipient of the Keio Medical Science Prize in rec... |
| 18.09.2025 | Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-Directed ADC TRODELVY® in Metastatic Breast Cancer | Completion of Phase 1b safety run-in and determination of recommended Phase 2 dose (RP2D) enables advancement into expansion cohorts for both hormone receptor-positive, HER2-negative (HR+/HER2−) and triple-negative (mTNBC) and metastatic br... |
| 03.09.2025 | Galvanize Therapeutics Raises $100 Million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease | Sofinnova Partners leads premier investor syndicate backing Galvanize's breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD.
REDWO... |
| 28.08.2025 | Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes | Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases
Replicate will receive research funding and could potentially receive up to a... |
| 31.07.2025 | Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board | Former Chief Scientific Officer & President of R&D at Pfizer, Dr. Mikael Dolsten brings decades of R&D and strategic leadership experience in pharmaceutical medicine to guide Marengo's next phase of growth and value creation
Wor... |
| 02.07.2025 | Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancer... | Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H) supported by recent FDA fast track designationNew clini... |
| 30.06.2025 | Apple Tree Partners Statement Regarding LP Litigation | Updated June 30, 2025
On May 30, 2025, Apple Tree Partners (ATP)’s fund ATP Life Science Ventures initiated litigation by filing a Complaint against its controlling limited partners (LPs) Rigmora Biotech Investor One LP and Rigmora Biotech ... |
| 24.06.2025 | Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease | BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson, MD, MPH, as Chief Development Officer. The company... |
| 11.06.2025 | Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases | Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases
Deep Apple is eligible to receive up to $812 million, including an upfront payment, research c... |
| 21.05.2025 | Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors | Appointment supports continued momentum of the company's rapidly accelerating precision oncology development strategy
CAMBRIDGE, Mass., May 21, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneeri... |
| 20.05.2025 | New Study Published on the Safety and Feasibility of Pulsed Electric Field Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection | Innovative technology offers promising non-thermal approach to soft tissue ablation without compromising sensitive structures.
REDWOOD CITY, Calif., May 20, 2025 /PRNewswire/ -- A new publication featuring Aliya® PEF has been published in t... |
| 08.05.2025 | Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer | STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead's Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers
CAMBRIDGE, Mass., May 8, 2025 /PR... |
| 06.05.2025 | Ascidian Therapeutics Announces Formation of Scientific Advisory Board | BOSTON, May 6, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the formation of its Scientific Advisory Board (SAB). These globally recognized leaders in ... |
| 29.04.2025 | Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting | Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors
AU-007’s unique clinical activity includes CD8 effector T c... |
| 25.04.2025 | Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Pre... | Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose range
Invikafusp alfa (STAR0602) demonstrates pan-tumor selectiv... |
| 21.04.2025 | Aethon Therapeutics to Share Preclinical and Discovery-Stage Updates on KRAS-G12C Hapten-Peptide Immunotherapies at AACR 2025 | New York, April 21, 2025 — Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, will present u... |
| 14.04.2025 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma | LARKSPUR, Calif., April 14, 2025 – Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of immune-activating antibody therapeutics, today announced dosing of its first patient with a combina... |
| 25.03.2025 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting | - |
| 25.03.2025 | Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 | Data to be presented from the STARt-001 trial demonstrating single agent anti-tumor activity
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for... |
| 25.03.2025 | Daniel Pierce Joins Initial Therapeutics as Chief Scientific Officer | SOUTH SAN FRANCISCO, Calif., March 24, 2025 — Initial Therapeutics, a life sciences
company discovering and developing new small-molecule therapeutics with a novel
platform to selectively modulate translation of pathogenic proteins by the r... |
| 20.03.2025 | Marengo Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune ... | Collaboration focuses on deeper exploration of Marengo's selective dual T cell agonists in oncology, and expansion of precision T cell depleting platform across a range of autoimmune diseases
Partnership with world-renowned T cell expert E.... |
| 03.03.2025 | Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen | Second licensed program created with Marengo's proprietary STAR precision T cell activation platform advances to IND-enabling phase
CAMBRIDGE, Mass., March 3, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 07.02.2025 | Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications | Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability
RBI-4000's potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global pub... |
| 05.02.2025 | Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board | Barcelona-based scientific leader brings insights and experience in translational oncology research and clinical development
CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company p... |
| 10.01.2025 | Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Company presentation scheduled for Thursday, January 16, 2025 at 10AM PT follows recent clinical progress
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel ap... |
| 08.01.2025 | Marengo's First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutationa... | Initial safety and efficacy data from Phase 1 STARt-001 trial showed promising single agent clinical activity in patients with different types of PD-1 resistant tumors including TMB-H colorectal cancer
Global Phase 2 clinical study for invi... |
| 20.12.2024 | Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe | Phase 1 STARt-001 data demonstrated a 25% Overall Response Rate and 50% Disease Control Rate observed at the targeted dose range during the Phase 1 investigation in patients harboring PD-1 resistant tumors with high tumor mutation burden, i... |
| 13.12.2024 | Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 | Results further validate company's novel and proprietary STAR bi-specific antibody platform for selective T cell activation in vivo
CAMBRIDGE, Mass., Dec. 13, 2024 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 03.12.2024 | Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program | Expanded agreement with Dana-Farber Cancer Institute enables further acceleration of Red Queen program in SARS-CoV-2 and advanced delivery options
Red Queen also has filed patents covering its novel pan-influenza treatment, for which the co... |
| 27.11.2024 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer | - |
| 09.11.2024 | Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting | STARt-001 is the first clinical study to evaluate Marengo’s novel, selective Vβ TCR agonist technology to promote in vivo expansion and reprogramming of tumor-infiltrating lymphocytes (TILs) in patients with advanced cancers
Invikafusp alfa... |
| 07.11.2024 | Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Phase 1 and preliminary Phase 2 data for AU-007 with low-dose aldesleukin show clinical activity, durable Treg reduction and correlated progression-free survival
Melanoma and non-small cell lung cancer prioritized for further Phase 2 clinic... |
| 30.10.2024 | Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting | Marengo's precision Vβ chain targeted T cell activator technology reinvigorates anti-tumor immune responses in refractory tumor models
Invikafusp alfa is being evaluated as a single-agent in an ongoing Phase 1/2 clinical trial (STARt-001) t... |
| 23.10.2024 | Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | AU-007 demonstrates continued distinction in IL-2 class, with unique profile of Treg reduction and correlated longer PFS outcomes, coupled with increases in tumor-killing Teffs
Phase 2 clinical efficacy and safety data to be presented befor... |
| 09.10.2024 | Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced that pharmacokinetic data for evaluatio... |
| 04.10.2024 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif., October 4, 2024 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of continued promisin... |
| 30.09.2024 | Braeburn Debuts Inspiring Docuseries Celebrating Advocates Uplifting Communities to Combat the Opioid Crisis | “Reframe and Reclaim: Shaping the Future of Recovery Stories” follows eight Philadelphia-based advocates in their efforts to educate and increase community awareness of this public health crisis
The three-part series is now available on the... |
| 27.09.2024 | Ascidian Therapeutics Named to 2024 "Endpoints 11" List of Most Promising Biotechs | BOSTON, September 27, 2024 – Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced that it has been named as one of the Endpoints 11 most promising biotech companies of 2024. This a... |
| 13.09.2024 | Marengo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa (STAR0602) and Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers | Invikafusp alfa has recently demonstrated single agent clinical activity across different PD-1 resistant cancers in the ongoing START-001 Phase1/2 clinical study
The collaboration plans to evaluate the combination of Marengo's first-in-clas... |
| 21.08.2024 | Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences | SAN DIEGO, Aug. 21, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, immuno-oncology and beyond, will be par... |
| 06.08.2024 | Apple Tree Partners Launches Red Queen Therapeutics to Bring Potentially Lifesaving Treatments to People at Greatest Risk from Viral Infections | Red Queen uses a novel antiviral platform to create pan-variant treatments for coronaviruses, influenza, RSV, and other serious viral diseases, with recent clinical validation in COVID-19 patients
Company operates with $55 million Series A ... |
| 06.08.2024 | Galvanize Therapeutics Completes Enrollment in Clinical Trial Evaluating Aliya® Pulsed Electric Field (PEF) System for Late-Stage Non-Small Cell Lung Cancer and Metastasis to the Lung | REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies for chronic bronchitis and solid tumors, has completed enrollment in the AFFINITY study evaluating Aliya... |
| 30.07.2024 | Nine Square Therapeutics Appoints James B. Summers, Ph.D., to Board of Directors and Scientific Advisory Board | Dr. Summers brings more than three decades of drug discovery and pharmaceutical research management experience, including the advancement of more than 20 compounds into clinical development
SAN FRANCISCO--(BUSINESS WIRE)--Nine Square Therap... |
| 02.07.2024 | Galvanize Appoints Executive Chairman and New Oncology-Focused Director to the Board of Directors | Doug Godshall Becomes Executive Chairman
Zhen Su, MD, MBA, Appointed to the Board of Directors to Bring Oncology Expertise
REDWOOD CITY, Calif., July 2, 2024 /PRNewswire/ -- Galvanize, a leader in Pulsed Electric Field (PEF) technologies, t... |
| 18.06.2024 | Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases | Ascidian to receive $42 million in initial payment, and up to $1.8 billion in research, clinical and commercial milestone payments, as well as commercial royalties
Per-target agreement enables Ascidian to pursue additional internal and coll... |
| 07.06.2024 | Ipsen and Marengo Therapeutics Announce Second Strategic Partnership to Advance Precision T Cell Engagers from Marengo’s Tri-STAR Platform | Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration
Research will focus on using Marengo’s TriSTAR platform to reinvi... |
| 28.05.2024 | Galvanize Receives FDA Clearance for the INUMI Flex Endoscopic Needle, Expanding its Aliya® Pulsed Electric Field (PEF) Portfolio for Soft Tissue Ablation | First Commercially Available Endoscopic Pulsed Electric Field Ablation System for Soft Tissue Lesions
REDWOOD CITY, Calif., May 28, 2024 /PRNewswire/ -- Galvanize today announced that it received U.S. Food and Drug Administration 510(k) reg... |
| 23.05.2024 | Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting | Preliminary results show durable anti-tumor activity in multiple solid tumor types among heavily pre-treated patients, including patients whose tumors have progressed through checkpoint inhibitors
The results confirm the ability of AU-007, ... |
| 15.05.2024 | Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007 | Combination of novel IL-2 therapeutic AU-007, Bavencio® (avelumab) and aldesleukin in Phase 2 cohort of AU-007 clinical trial to build on compelling preclinical evidence of eradication of solid tumors
LARKSPUR, Calif., May 15, 2024 – Aulos ... |
| 11.05.2024 | Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel Self-Replicating RNA at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | - |
| 24.04.2024 | Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting | - |
| 22.04.2024 | Replicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced accepta... |
| 18.04.2024 | Initial Therapeutics Names Peter DiLaura as CEO | SOUTH SAN FRANCISCO, Calif., April 18, 2024 (PR NEWSWIRE) – Initial Therapeutics Inc., a life sciences company discovering and developing new small-molecule therapeutics with a novel platform to selectively modulate translation of pathogeni... |
| 04.04.2024 | Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs | Aethon will apply its proprietary HapImmune™ platform to create novel antibodies that home in on cancer neoantigens generated by treatment with RAS inhibitors
Collaboration focuses on key Revolution Medicines pipeline programs
NEW YORK, Apr... |
| 02.04.2024 | Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen | A novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment
Marengo to receive an associated milestone payment and eligible for additional future milestone payments, and tiered royalties
CAMBRIDGE, Mass., April... |
| 01.03.2024 | Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences | SAN DIEGO, March 1, 2024 (PRNewswire) -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, will be participating in the follo... |
| 14.02.2024 | Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology | Replicate's srRNA vaccine elicited a protective immune response that met the WHO threshold for protection at unparalleled low doses
Threshold for protection achieved with just a single dose of vaccine
RBI-4000 well-tolerated at all doses te... |
| 29.01.2024 | Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies | ACDN-01 is the first RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease
Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half... |
| 29.01.2024 | Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies | ACDN-01 is the first RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease
Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first hal... |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers | Preliminary Phase 2 data in melanoma, renal cell carcinoma anticipated to be presented by mid-2024
LARKSPUR, Calif. (BUSINESS WIRE) -- Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the developmen... |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers | - |
| 05.01.2024 | Novel Compound Protects Against Infection by Virus that Causes COVID-19, Preliminary Studies Show | Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters
Clinical trial now under way of compound's effectiveness as a nasal spray in humans
Approach has the pote... |
| 05.01.2024 | Novel Compound Protects Against Infection by Virus that Causes COVID-19, Preliminary Studies Show | Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters |
| 18.12.2023 | Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors | Phase 2 study follows on positive Phase 1 data showing early anti-tumor activity in heavily pre-treated patients and well-tolerated safety profile |
| 18.12.2023 | Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors | Phase 2 study follows on positive Phase 1 data showing early anti-tumor activity in heavily pre-treated patients and well-tolerated safety profile
Phase 2 portion to assess AU-007 in combination with low-dose Proleukin®, with initial expan... |
| 14.12.2023 | Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models | Conducting entirely virtual screens of multi-billion molecule virtual libraries, Deep Apple can quickly identify hits that promote specific signaling in GPCRs and other target classes
San Francisco-based company created by ATP with academi... |
| 14.12.2023 | Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models | Conducting entirely virtual screens of multi-billion molecule virtual libraries, Deep Apple can quickly identify hits that promote specific signaling in GPCRs and other target classes |
| 07.12.2023 | Marengo Therapeutics and Kings College London Announce Publication in Science Advances Highlighting the Discovery of a New Approach to T Cell Activation | Antibodies to germline-encoded TCR β-chain alleles drive T cells to distinct memory-like effector states and reveal the potential to modulate the germline T cell repertoire. |
| 06.12.2023 | Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine | Marengo's first pan-tumor Vβ T cell activator, STAR0602, expands Vβ6 T cells that drive potent, single agent anti-tumor activity via a distinct mechanism to anti-PD1 therapies |
| 13.11.2023 | Nereid Therapeutics Appoints Michael Kauffman as CEO | Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid’s work to advance multiple programs towards the clinic |
| 13.11.2023 | Nereid Therapeutics Appoints Michael Kauffman as CEO | Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid’s work to advance multiple programs towards the clinic
BOSTON, November 13, 2023 /PRNewswire/ -... |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, including Stargardt disease, and advance key pipeline programs
in CNS and neuromuscular diseases
Ascidian anticipates filing an IND and initiating... |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, including Stargardt disease, and advance key pipeline programs
in CNS and neuromuscular diseases |
| 06.11.2023 | Galvanize Therapeutics Announces Promising Data on the Aliya™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer | SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies, unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SIT... |
| 06.11.2023 | Galvanize Therapeutics Announces Promising Data on the Aliya™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer | SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies, unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SIT... |
| 03.11.2023 | New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting | - |
| 03.11.2023 | New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Preliminary evidence of anti-tumor activity observed in heavily pre-treated patients, including those whose tumors progressed through checkpoint inhibitors
Further development of AU-007 to continue in combination with low-dose aldesleukin,... |
| 14.10.2023 | New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuti... | - |
| 14.10.2023 | New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuti... | Interim data from an ongoing trial support overall mechanism of action of AU-007, a computationally designed human monoclonal antibody, in decreasing Tregs while increasing effector T cells and NK cells
Clinical efficacy and safety data fr... |
| 04.10.2023 | Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic... | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced the presentation of encouraging pha... |
| 04.10.2023 | Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic... | - |
| 27.09.2023 | Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that new safety and efficacy data f... |
| 27.09.2023 | Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting | - |
| 20.09.2023 | Galvanize Therapeutics Begins U.S. Clinical Study Using Aliya™ Pulsed Electric Field (PEF) for Stage IV Non-Small Cell Lung Cancer or Metastasis to the Lung | First patient treated in the U.S. with Aliya PEF delivered via an endobronchial approach with robotic-assisted navigation |
| 20.09.2023 | Galvanize Therapeutics Begins U.S. Clinical Study Using Aliya™ Pulsed Electric Field (PEF) for Stage IV Non-Small Cell Lung Cancer or Metastasis to the Lung | First patient treated in the U.S. with Aliya PEF delivered via an endobronchial approach with robotic-assisted navigation
REDWOOD CITY, Calif. , Sept. 20, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc. today announced the treatment of t... |
